[go: up one dir, main page]

RU2018118176A - Липосомы, содержащие проникающие в клетки пептиды и тетраэфирные липиды, для пероральной доставки макромолекул - Google Patents

Липосомы, содержащие проникающие в клетки пептиды и тетраэфирные липиды, для пероральной доставки макромолекул Download PDF

Info

Publication number
RU2018118176A
RU2018118176A RU2018118176A RU2018118176A RU2018118176A RU 2018118176 A RU2018118176 A RU 2018118176A RU 2018118176 A RU2018118176 A RU 2018118176A RU 2018118176 A RU2018118176 A RU 2018118176A RU 2018118176 A RU2018118176 A RU 2018118176A
Authority
RU
Russia
Prior art keywords
liposome composition
composition according
paragraphs
seq
lipids
Prior art date
Application number
RU2018118176A
Other languages
English (en)
Other versions
RU2743431C2 (ru
RU2018118176A3 (ru
Inventor
Филипп УЛЬ
Макс ЗАУТЕР
Уве Хаберкорн
Вальтер Мир
Герт ФРИККЕР
Original Assignee
Универзитет Хайдельберг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Универзитет Хайдельберг filed Critical Универзитет Хайдельберг
Publication of RU2018118176A publication Critical patent/RU2018118176A/ru
Publication of RU2018118176A3 publication Critical patent/RU2018118176A3/ru
Application granted granted Critical
Publication of RU2743431C2 publication Critical patent/RU2743431C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (18)

1. Липосомная композиция, содержащая липосомы, причем указанные липосомы содержат
(a) тетраэфирные липиды (TEL) и
(b) проникающие в клетки пептиды (CPP),
где указанные CPP присоединены к соединению, которое является частью липидного бислоя липосомы.
2. Липосомная композиция по п.1, где указанные TEL получены из Sulfolobus sp.
3. Липосомная композиция по п.2, где указанные TEL получены из Sulfolobus acidocaldarius.
4. Липосомная композиция по любому из пп. 1-3, в которой указанные TEL выбраны из группы, состоящей из глицерилкалдитилтетраэфира (GCTE), диглицерилтетраэфира (DGTE) и их сочетаний.
5. Липосомная композиция по любому из пп. 1-4, в которой указанные липосомы содержат указанные TEL в количестве от 1 до 10 моль.% на основе общего количества липидов.
6. Липосомная композиция по любому из пп. 1-5, в которой указанные CPP выбраны из группы, состоящей из линейного или циклизованного пенетратина (SEQ ID № 1), пептида TAT (трансактиватор транскрипции) (SEQ ID № 2), MAP (модельный амфипатический пептид) (SEQ ID № 3), R9 (SEQ ID № 4), pVEC (SEQ ID № 5), транспортана (SEQ ID № 6) и MPG (SEQ ID № 7), их сочетаний и их димеров.
7. Липосомная композиция по любому из пп. 1-6, в которой указанные липосомы содержат указанные CPP в количестве от 0,1 до 1 моль.% на основе общего количества липидов.
8. Липосомная композиция по любому из пп. 1-7, в которой указанное соединение, к которому присоединены указанные CPP, выбраны из группы, состоящей из холестерина и его производных, фосфолипидов, лизофосфолипидов и тетраэфирных липидов.
9. Липосомная композиция по любому из пп. 1-8, в которой указанные CPP присоединены ковалентно.
10. Липосомная композиция по любому из пп. 1-9, в которой указанные CPP присоединены через линкер.
11. Липосомная композиция по п.10, в которой указанный линкер выбран из группы, состоящей из бифункциональных PEG-линкеров.
12. Липосомная композиция по любому из пп. 1-11, которая дополнительно содержит по меньшей мере одно терапевтическое средство и/или по меньшей мере одно диагностическое средство.
13. Липосомная композиция по любому из пп. 1-12 для применения в медицине.
14. Липосомная композиция для применения по п.13, где указанная композиция предназначена для перорального введения.
15. Применение липосомной композиции по любому из пп. 1-12 для пероральной доставки по меньшей мере одного терапевтического средства и/или по меньшей мере одного диагностического средства.
RU2018118176A 2015-10-21 2016-10-11 Липосомы, содержащие проникающие в клетки пептиды и тетраэфирные липиды, для пероральной доставки макромолекул RU2743431C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15003011.2 2015-10-21
EP15003011.2A EP3158992A1 (en) 2015-10-21 2015-10-21 Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules
PCT/EP2016/001682 WO2017067642A1 (en) 2015-10-21 2016-10-11 Liposomes containing cell penetrating peptides and tetraetherlipids for the oral delivery of macromolecules

Publications (3)

Publication Number Publication Date
RU2018118176A true RU2018118176A (ru) 2019-11-21
RU2018118176A3 RU2018118176A3 (ru) 2020-02-26
RU2743431C2 RU2743431C2 (ru) 2021-02-18

Family

ID=54345413

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018118176A RU2743431C2 (ru) 2015-10-21 2016-10-11 Липосомы, содержащие проникающие в клетки пептиды и тетраэфирные липиды, для пероральной доставки макромолекул

Country Status (8)

Country Link
US (1) US10653796B2 (ru)
EP (2) EP3158992A1 (ru)
JP (1) JP6689378B2 (ru)
CN (1) CN108135846B (ru)
ES (1) ES2870223T3 (ru)
RU (1) RU2743431C2 (ru)
WO (1) WO2017067642A1 (ru)
ZA (1) ZA201801514B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909487T3 (es) * 2017-03-30 2022-05-06 Univ Heidelberg Composiciones liposomales y formas solidas de dosificación oral que comprenden las mismas
US12194105B2 (en) 2018-02-21 2025-01-14 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for new antimicrobial agents with secondary mode of action provided by conjugation of an antimicrobial to a guanidinium-rich molecular transporter
EP3628309A1 (en) * 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
CN109392900B (zh) * 2018-10-25 2020-05-19 武汉康科植保技术有限公司 一种含有细胞穿透肽的纳米脂质体及其制备方法和应用
PL242410B1 (pl) * 2019-01-31 2023-02-20 Gdanski Univ Medyczny Sposób otrzymywania koniugatów wankomycyny i TP10, koniugaty otrzymane tym sposobem oraz ich zastosowanie w leczeniu przeciwbakteryjnym
EP3708151A1 (en) * 2019-03-15 2020-09-16 Technische Universität Wien Method for producing a composition comprising archaeal lipids from a sulfolobus cell culture
CN110075317B (zh) * 2019-04-11 2022-03-08 天津大学 利用穿膜肽改性葡聚糖制备葡聚糖-穿膜肽高分子脂质体及其制备方法、应用
CN114007653B (zh) * 2019-05-05 2024-02-09 复旦大学 药物递送载体以及使用其的药物制剂
CN110201147A (zh) * 2019-05-23 2019-09-06 中山市粤美医疗生物科技有限公司 一种包含肽的组合物及其制备方法
EP4181881A1 (en) * 2020-07-14 2023-05-24 Universität Heidelberg Oral pharmaceutical compositions comprising lipid conjugates
WO2023070429A1 (zh) * 2021-10-28 2023-05-04 谛邈生物科技(北京)有限公司 牛奶外泌体在制备药物载体中的应用
CN116549609A (zh) * 2022-01-27 2023-08-08 北京良远生物医药研究有限公司 一种il2制剂、其制备方法及应用
CN114452258B (zh) * 2022-03-09 2023-07-25 成都大学 利拉鲁肽脂质体制剂及其制备方法和应用
WO2025046121A1 (en) 2023-09-01 2025-03-06 Novoarc Gmbh Lipid nanoparticle with nucleic acid cargo and ionizable lipid
CN120661400B (zh) * 2025-08-25 2025-11-11 烟台华康生物医药科技有限公司 一种含有海参肽的抗衰组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502087A (ja) * 1995-12-15 2000-02-22 ナショナル リサーチ カウンシル オブ カナダ アジュバンドおよび送達賦形剤としての、アーケオソーム類、補酵素ｑ▲下１０▼を含有するアーケオソーム類、および補酵素ｑ▲下１０▼を含有する他の種類のリポソーム類
DE69820465T2 (de) * 1997-06-23 2004-09-16 Alza Corp., Mountain View Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren
WO2010054326A2 (en) * 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
CN101744768A (zh) * 2010-03-19 2010-06-23 上海交通大学 基于四醚脂质的蛋白或核酸药物脂质体制剂及其制备方法
KR101198715B1 (ko) * 2010-05-14 2012-11-13 한국생명공학연구원 핵산 및 친수성 음이온 화합물의 고효율 포획을 위한 비대칭 리포솜 및 이의 제조방법
US20140112979A1 (en) * 2011-07-04 2014-04-24 Statens Serum Institut Methods for producing liposomes
US20130251783A1 (en) * 2011-09-14 2013-09-26 Universitat Heidelberg Liposomes containing permeation enhancers for oral drug delivery
WO2013059617A1 (en) * 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
US9393320B2 (en) * 2011-12-07 2016-07-19 Universidade Do Minho Liposomes and its production method
CN110464709A (zh) * 2012-08-10 2019-11-19 德克萨斯州大学系统董事会 用于治疗中风的神经保护性脂质体组合物和方法

Also Published As

Publication number Publication date
JP2018532740A (ja) 2018-11-08
ES2870223T3 (es) 2021-10-26
RU2743431C2 (ru) 2021-02-18
EP3364952B1 (en) 2021-02-24
CN108135846B (zh) 2022-02-18
RU2018118176A3 (ru) 2020-02-26
EP3364952A1 (en) 2018-08-29
US20180303956A1 (en) 2018-10-25
WO2017067642A1 (en) 2017-04-27
CN108135846A (zh) 2018-06-08
US10653796B2 (en) 2020-05-19
ZA201801514B (en) 2019-07-31
JP6689378B2 (ja) 2020-04-28
EP3158992A1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
RU2018118176A (ru) Липосомы, содержащие проникающие в клетки пептиды и тетраэфирные липиды, для пероральной доставки макромолекул
US12220387B2 (en) Fusion comprising a cell penetrating peptide, a multi epitope and a TLR peptide agonist for treatment of cancer
Futaki et al. Cell-surface interactions on arginine-rich cell-penetrating peptides allow for multiplex modes of internalization
Rin Jean et al. Molecular vehicles for mitochondrial chemical biology and drug delivery
Borrelli et al. Cell penetrating peptides as molecular carriers for anti-cancer agents
Vasconcelos et al. Therapeutic potential of cell-penetrating peptides
J Boohaker et al. The use of therapeutic peptides to target and to kill cancer cells
Cerrato et al. Cell-penetrating peptides with intracellular organelle targeting
Hoyer et al. Peptide vectors for the nonviral delivery of nucleic acids
Kaur et al. TLR2 agonistic small molecules: detailed structure–activity relationship, applications, and future prospects
Fonseca et al. Recent advances in the use of cell-penetrating peptides for medical and biological applications
US20180133327A1 (en) Cell Penetrating Peptides and Complexes Comprising the Same
Iwasa et al. Cellular uptake and subsequent intracellular trafficking of R8-liposomes introduced at low temperature
RU2019134554A (ru) Липосомальные композиции и содержащие их твердые пероральные лекарственные формы
ES2575395T3 (es) Composiciones para la transfección de células
CA2884677A1 (en) Cell penetrating peptides derived from the epstein barr virus, compositions and methods thereof
Simerska et al. Modern lipid‐, carbohydrate‐, and peptide‐based delivery systems for peptide, vaccine, and gene products
Trabulo et al. Cell-penetrating peptides as nucleic acid delivery systems: from biophysics to biological applications
CN114727957A (zh) 用于递送活性剂或治疗剂的水包油乳剂制剂
CA2694011C (en) Survivin peptides as cancer vaccines
Mokhtarieh et al. Novel cell penetrating peptides with multiple motifs composed of RGD and its analogs
ES2775577T3 (es) Compuesto de curcufenol para usar en el tratamiento del cáncer
KR20150130249A (ko) 세포 투과성 펩티드 및 이를 이용한 생물학적 활성 물질의 전달방법
JP6240570B2 (ja) 脂質粒子および核酸送達キャリア
B Lopes et al. Potential of peptide-based enhancers for transdermal delivery